Financials • LeonaBio

LONA

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2018	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2019	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	0	-64	-12	0%	L	417	L	-254	-	-48	-2	97	-49	0	0	-	-
12/2022	0	-103	-12	0%	L	427	L	-200	-	-83	-1	1	-84	0	0	-	-
12/2023	0	-124	-123	0%	L	439	L	-147	-	-111	-0	0	-112	0	0	-	-
12/2024	0	-100	-12	0%	L	451	L	-51	-	-108	-0	0	-108	0	0	-	-
12/2025	0	-101	-123	0%	L	540	L	-88	-	-52	0	82	-52	0	0	-	-

To see all financials—including updated, you must be Premium.